PALO ALTO, Calif., May 18, 2020 /PRNewswire/ -- As further
evidence of the strong industry response to a potential new
paradigm in the treatment of cancer, Varian (NYSE: VAR) today
announced that Proton Therapy Pte., Ltd. (http://www.proton.sg/) in
Singapore has joined the
FlashForward™ Consortium. Now including 20 members,
representing nine countries, the Consortium is focused on
preclinical research, clinical implementation, and advocacy efforts
of FLASH therapy.
Varian is installing a Varian ProBeam® Compact system
equipped with a 360-degree gantry and integrated cone beam CT at
Proton Therapy Pte., Ltd.'s site in Singapore. The system is located at the
Advanced Medicine Oncology Centre at Biopolis, an international
biomedical research hub in Singapore, and provides clinicians in the
region a viable path to potential next-generation treatments such
as FLASH Therapy.
FLASH therapy is currently defined as a non-invasive treatment
using an external beam delivered in high doses, at ultra-high
speeds (less than 1 second), and in one to three sessions.
Traditional external beam treatments are delivered in significantly
lower doses per session typically spread out over an average of 25
sessions. Working groups in the FlashForward Consortium are
identifying preclinical study designs for understanding this
therapy, developing and sharing protocols that will enable a safe
and quality clinical start for new users, and assisting with
regulatory and advocacy efforts.
"We are proud to welcome Proton Therapy Pte., Ltd. to the
FlashForward Consortium," said Kolleen
Kennedy, chief growth officer and president of Proton
Therapy Solutions, Varian. "Representing our first member from
Southeast Asia, they are a
significant new addition to the Consortium. Their location inside
Biopolis Singapore offers the Consortium an opportunity to partner
with other global luminary researchers as we continue to
investigate the clinical implementation of FLASH Therapy."
"There are a number of open questions that need to be answered
as it pertains to FLASH therapy," said Dr. Djeng Shih Kien,
chairman, Proton Therapy Pte., Ltd. "We believe that our
partnership with the rest of the FlashForward Consortium will help
us answer many of these questions. We look forward to the research
ahead of us and are excited for the future of proton therapy in
Southeast Asia and the clinical
potential of FLASH."
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Aimee Corso
Health + Commerce, on behalf of Varian
+1 (310) 780-2661
aimee@healthandcommerce.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-announces-new-addition-to-flashforward-consortium-301060278.html
SOURCE Varian